Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

NCT04449549 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

82

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Nilotinib and Paclitaxel

Sponsor

National Cancer Institute (NCI)